To HTA or not to HTA: identifying the factors influencing the rapid review outcome in Ireland

Simple item page
dc.contributor.authorMurphy, Aileen
dc.contributor.authorRedmond, Sandra
dc.date.accessioned2019-08-12T14:10:57Z
dc.date.available2019-08-12T14:10:57Z
dc.date.issued2019-03-06
dc.description.abstractObjectives: Reimbursement systems are evolving and endeavor to balance access and affordability. One such evolution in Ireland is the compulsory rapid review (RR) process, the outcome from which is a recommendation for a health technology assessment (HTA) or no HTA. For drugs that avoid an HTA, evaluation times are shorter, lengthy price negotiations are avoided, and access is faster. In the absence of formal decision-making criteria around the requirement of an HTA, this study examines the factors influencing the outcome of the RR process in Ireland. Methods: A database was developed combining data from publicly available sources for drug evaluations conducted by the National Centre for PharmacoEconomics (NCPE) (January 2010-June 2017, n = 296). Because Irish cost data were not publicly available for all drugs, cost data from the Scottish Medicines Consortium were employed as a proxy. Employing logistic regressions, the factors influencing the RR outcome are revealed. Results: After an RR, an HTA was recommended for 55% of drugs. The regression results revealed therapeutic area (endocrine, musculoskeletal, and neoplasm), first-in-class and orphan disease increased the probability of an HTA. Furthermore, when proxy costs were included, results revealed that every €1000 increase in annual drug costs per patient increased the probability of an HTA being required by 1% and that an HTA was more likely than no HTA when annual drug costs exceeded €15 000. Conclusion: Given the current focus on access and affordability, this study identifies the factors influencing the requirement of an HTA in Ireland.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationMurphy, A. and Redmond, S. (2019) 'To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland', Value in Health, 22(4), pp. 385-390. doi: 10.1016/j.jval.2018.10.011en
dc.identifier.doi10.1016/j.jval.2018.10.011en
dc.identifier.endpage390en
dc.identifier.issn1098-3015
dc.identifier.issued4en
dc.identifier.journaltitleValue in Healthen
dc.identifier.startpage385en
dc.identifier.urihttps://hdl.handle.net/10468/8306
dc.identifier.volume22en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urihttp://www.sciencedirect.com/science/article/pii/S109830151930049X
dc.rights© 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 licenseen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectCost savingsen
dc.subjectCost-benefit analysisen
dc.subjectDrug approvalen
dc.subjectDrug costsen
dc.subjectHealth servicesen
dc.subjectAccessibilityen
dc.subjectOrphan drug productionen
dc.subjectOutcome and process assessment (health care)en
dc.subjectReimbursement mechanismsen
dc.subjectTechnology assessmenten
dc.subjectTechnology assessment, biomedicalen
dc.subjectTime factorsen
dc.subjectWorkflowen
dc.titleTo HTA or not to HTA: identifying the factors influencing the rapid review outcome in Irelanden
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10680.pdf
Size:
224.73 KB
Format:
Adobe Portable Document Format
Description:
Accepted version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Economics - Journal Articles
Cork University Business School - Journal Articles